Global X S&P Biotech ETF (ASX:CURE)
Australia
· Delayed Price · Currency is AUD 62.73
-0.87 (-1.37%)
Apr 28, 2026, 3:16 PM AEST
47.63% (1Y)
| Assets | 41.92M |
| Expense Ratio | 45.00% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +47.64% |
| Volume | 605 |
| Open | 63.50 |
| Previous Close | 63.60 |
| Day's Range | 62.73 - 63.50 |
| 52-Week Low | 40.17 |
| 52-Week High | 65.95 |
| Beta | 0.33 |
| Holdings | 10 |
| Inception Date | Nov 8, 2018 |
About CURE
The Global X S&P Biotech ETF (CURE) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.
Asset Class Equity
Category Health Care
Stock Exchange Australian Securities Exchange
Ticker Symbol CURE
Provider Global X
Index Tracked S&P Biotechnology Select Industry
Performance
CURE had a total return of 47.64% in the past year. Since the fund's inception, the average annual return has been 6.60%, including dividends.
Top 10 Holdings
14.10% of assets| Name | Symbol | Weight |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | APLS | 1.72% |
| Revolution Medicines, Inc. | RVMD | 1.57% |
| Summit Therapeutics Inc. | SMMT | 1.52% |
| Travere Therapeutics, Inc. | TVTX | 1.45% |
| Twist Bioscience Corporation | TWST | 1.34% |
| TG Therapeutics, Inc. | TGTX | 1.32% |
| Alkermes plc | ALKS | 1.31% |
| Apogee Therapeutics, Inc. | APGE | 1.30% |
| Madrigal Pharmaceuticals, Inc. | MDGL | 1.30% |
| Beam Therapeutics Inc. | BEAM | 1.27% |